NaNotics LLC, a nanomedical company focused on developing and commercializing NaNots™, a novel subtractive nanoparticle that treats disease by capturing and clearing pathogenic molecules from blood,d.
Latest Press Releases
— Our press release programs work hand in hand with our SEO programs to provide a rock solid positioning in all major search engines so as to contemplate the visibility of your message for Worldwide Pharmaceutical industry.
Labcorp (NYSE: LH), a leading global life sciences company, that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc.
GreenLight Biosciences (ENVI) and IAVI, a nonprofit scientific research organization, work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.
AppliedVR, a pioneer advancing the next generation of immersive therapeutics, that the U.S.
iDklic the extension of technology partnership with VPHARMA for an additional five years, providing the PharmaSeen window shopping digital signage solution to 40 VPHARMA pharmacy locations throughout Belgium.
KODOCARE Pharmacy they are now administering COVID-19 vaccine to children 5 to 11 years old.
ARTiFACTS, creator of the world's first blockchain-based platform for scientific and academic research, today announced a partnership with the Distributed Pharmaceutical Analysis Lab (DPAL) at the University of Notre Dame to develop a prototype solution for tracking pharmaceutical chain-of-custody information in real-time using distributed ledger technology.
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, the positive efficacy and safety results from an investigator-initiated, Phase 2 clinical trial of Silmitasertib in approximately 20 patients with moderate COVID-19.
Mobilogix, the leading provider of cost-optimized state-of-the-art cellular IoT solutions, a strategic partnership with rfxcel, part of Antares Vision Group and a leading serialization and traceability enterprise solution provider.
The race to develop drugs to treat Alzheimer's disease, which currently affects an estimated 6 million Americans, has been slow-going.